Regeneration and repair of neural tissue using postpartum-derived cells
First Claim
Patent Images
1. A method of providing factors to a patient having a neurodegenerative condition comprising administering to the patient a composition comprising a conditioned medium generated by culturing cells isolated from human umbilical cord tissue substantially free of blood, wherein said cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype;
- exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype, and lack production of CD117; and
wherein the method promotes cell survival and/or neuronal differentiation and wherein the factors are selected from the group consisting of brain-derived neurotrophic factor (BDNF), interleukin-6 (IL-6), granulocyte chemotactic protein-2 (GCP-2), transforming growth factor beta2 (TGFbeta2), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), keratinocyte growth factor (KGF), platelet derived growth factor (PDGF-bb), heparin-binding epidermal growth factor (HB-EGF) and combinations thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of neural tissue using the postpartum-derived cells are also disclosed.
-
Citations
7 Claims
-
1. A method of providing factors to a patient having a neurodegenerative condition comprising administering to the patient a composition comprising a conditioned medium generated by culturing cells isolated from human umbilical cord tissue substantially free of blood, wherein said cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype;
- exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype, and lack production of CD117; and
wherein the method promotes cell survival and/or neuronal differentiation and wherein the factors are selected from the group consisting of brain-derived neurotrophic factor (BDNF), interleukin-6 (IL-6), granulocyte chemotactic protein-2 (GCP-2), transforming growth factor beta2 (TGFbeta2), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), keratinocyte growth factor (KGF), platelet derived growth factor (PDGF-bb), heparin-binding epidermal growth factor (HB-EGF) and combinations thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7)
- exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype, and lack production of CD117; and
Specification